These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24750439)

  • 1. Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products.
    Johnston JD; Feldschreiber P
    Br J Clin Pharmacol; 2014 Jun; 77(6):939-46. PubMed ID: 24750439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines.
    Johnston JD; Feldschreiber P
    Br J Clin Pharmacol; 2014 Mar; 77(3):421-6. PubMed ID: 23738917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
    Jackson EL; Feldschreiber P; Breckenridge A
    Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UK medicines regulation: responding to current challenges.
    Richards N; Hudson I
    Br J Clin Pharmacol; 2016 Dec; 82(6):1471-1476. PubMed ID: 27580254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From lipoproteins to chondrocytes: a brief summary of the European Medicines Agency's regulatory guidelines for advanced therapy medicinal products.
    Kassim SH; Somerville RP
    Hum Gene Ther; 2013 Jun; 24(6):568-70. PubMed ID: 23777464
    [No Abstract]   [Full Text] [Related]  

  • 13. TradReg 2013: regulation of herbal and traditional medicinal products--European and global strategies--international symposium.
    Cranz H; Anquez-Traxler C
    J Ethnopharmacol; 2014 Dec; 158 Pt B():495-7. PubMed ID: 25281419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
    Stephenson T
    Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmaceutical industry and health reform: lessons from Europe.
    Hutton J; Borowitz M; Oleksy I; Luce BR
    Health Aff (Millwood); 1994; 13(3):98-111. PubMed ID: 7927165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
    Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
    Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementary Protection Certificates for medicinal products: where are we now and what challenges lay ahead?
    Miles J
    Pharm Pat Anal; 2012 Jul; 1(3):275-84. PubMed ID: 24236841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new European legislation on traditional herbal medicines: main features and perspectives.
    Silano M; De Vincenzi M; De Vincenzi A; Silano V
    Fitoterapia; 2004 Mar; 75(2):107-16. PubMed ID: 15030913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should Anthroposophic Medicinal Products Be Regulated in Europe?
    Michaux G
    Eur J Health Law; 2017 Mar; 24(1):46-66. PubMed ID: 29210253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.